In response to 'Factors associated with the development of gastrointestinal adverse events in dogs with multicentric lymphoma treated with CHOP or CEOP-based protocols: a multi-institutional, retrospective study' by Treggiari et al.

Doxorubicin may cause more GI adverse events than epirubicin in canine lymphoma treatment.

This multi-institutional, retrospective study aimed to analyze the frequency and severity of gastrointestinal (GI) adverse events in dogs with multicentric lymphoma treated with multi-agent chemotherapy protocols, specifically CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or CEOP (cyclophosphamide, epirubicin, vincristine, and prednisone). A total of 178 dogs were included, with 114 (64.1%) receiving epirubicin and 64 (35.9%) receiving doxorubicin. GI adverse events occurred in 46 dogs (40.3%) in the epirubicin group and 36 dogs (56.2%) in the doxorubicin group. Statistical analysis revealed that male neutered dogs, those younger than 10 to 15 years, receiving epirubicin at a dosage of 1 mg/kg, and those with stage V disease were at a higher risk of developing GI adverse events. The study concluded that while both doxorubicin and epirubicin are associated with GI adverse events, doxorubicin may have a higher incidence. The authors suggest that these findings could aid in preventing such adverse events, though further prospective studies are necessary to determine the optimal anthracycline choice to minimize GI toxicity. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/40320245/?utm_source=openai))

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.